Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria

Pegvaliase (Palynziq®) was FDA approved in 2018 as an enzyme substitution therapy in patients with Phenylketonuria. However, various drug induced hypersensitivity adverse events (HAEs) have been reported. We present a case of Pegvaliase (Palynziq®) induced anaphylaxis and successful desensitization....

Descripción completa

Detalles Bibliográficos
Autores principales: Patrawala, Meera, Kuruvilla, Merin, Li, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063228/
https://www.ncbi.nlm.nih.gov/pubmed/32181140
http://dx.doi.org/10.1016/j.ymgmr.2020.100575
_version_ 1783504674916139008
author Patrawala, Meera
Kuruvilla, Merin
Li, Hong
author_facet Patrawala, Meera
Kuruvilla, Merin
Li, Hong
author_sort Patrawala, Meera
collection PubMed
description Pegvaliase (Palynziq®) was FDA approved in 2018 as an enzyme substitution therapy in patients with Phenylketonuria. However, various drug induced hypersensitivity adverse events (HAEs) have been reported. We present a case of Pegvaliase (Palynziq®) induced anaphylaxis and successful desensitization. A 13-step desensitization protocol was performed using three solution concentrations of Palynziq with premedication of diphenhydramine and prednisone in an outpatient setting. The patient tolerated the desensitization and was able to continue Palynziq.
format Online
Article
Text
id pubmed-7063228
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-70632282020-03-16 Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria Patrawala, Meera Kuruvilla, Merin Li, Hong Mol Genet Metab Rep Short Communication Pegvaliase (Palynziq®) was FDA approved in 2018 as an enzyme substitution therapy in patients with Phenylketonuria. However, various drug induced hypersensitivity adverse events (HAEs) have been reported. We present a case of Pegvaliase (Palynziq®) induced anaphylaxis and successful desensitization. A 13-step desensitization protocol was performed using three solution concentrations of Palynziq with premedication of diphenhydramine and prednisone in an outpatient setting. The patient tolerated the desensitization and was able to continue Palynziq. Elsevier 2020-03-06 /pmc/articles/PMC7063228/ /pubmed/32181140 http://dx.doi.org/10.1016/j.ymgmr.2020.100575 Text en http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Short Communication
Patrawala, Meera
Kuruvilla, Merin
Li, Hong
Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria
title Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria
title_full Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria
title_fullStr Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria
title_full_unstemmed Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria
title_short Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria
title_sort successful desensitization of pegvaliase (palynziq®) in a patient with phenylketonuria
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063228/
https://www.ncbi.nlm.nih.gov/pubmed/32181140
http://dx.doi.org/10.1016/j.ymgmr.2020.100575
work_keys_str_mv AT patrawalameera successfuldesensitizationofpegvaliasepalynziqinapatientwithphenylketonuria
AT kuruvillamerin successfuldesensitizationofpegvaliasepalynziqinapatientwithphenylketonuria
AT lihong successfuldesensitizationofpegvaliasepalynziqinapatientwithphenylketonuria

Ejemplares similares